Analysts Are Bullish on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), uniQure (QURE)

Business Insider

12-05-2025

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and uniQure (QURE – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Iovance Biotherapeutics (IOVA)
In a report issued on May 9, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics, with a price target of $4.00. The company's shares closed last Friday at $1.75.
According to TipRanks.com, Lawson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.1% and a 35.4% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Adaptimmune Therapeutics, and Karyopharm Therapeutics.
Currently, the analyst consensus on Iovance Biotherapeutics is a Moderate Buy with an average price target of $13.83, a 612.9% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.
uniQure (QURE)
Wells Fargo analyst Yanan Zhu maintained a Buy rating on uniQure on May 9 and set a price target of $30.00. The company's shares closed last Friday at $12.79.
According to TipRanks.com, Zhu is ranked 0 out of 5 stars with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Crispr Therapeutics AG.
Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $36.86, representing a 203.4% upside. In a report issued on April 29, Leerink Partners also maintained a Buy rating on the stock with a $48.00 price target.